A year later, at the onset of Andrew’s illness, I was a fellow at Harvard University studying trends in mortality and life ...

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...